QIAGEN, world’s leading provider of technologies and products for separating and purifying nucleic acids, and GenIUL have reached an agreement for the production and sales of Propidium Monoazide (PMA), one of the current key reagents for viability PCR, besides Ethidium Monoazide (EMA) already offered by GenIUL.
It concerns the unique Sub Licensee from QIAGEN for the manufacturing and sales of Propidium Monoazide during an interim period. Nowadays GenIUL is the only company respecting the intellectual property rights related to the use of Propidium Monoazide for viability PCR.
The reagent is produced under strict and specific purity criteria and its functionality for viability PCR is tested for each batch. Additionally GenIUL takes care of certifying its high purity, structural integrity and diazide absence.
The product is presented in a metallic zip bag with 2 screw cap dark glass vials containing each 0, 5 mg of dry PMA: this format is easy to handle and has been specifically developed for viability PCR customers.
Thanks to the agreement with QIAGEN, GenIUL is now the first company that offers this licensed product specifically developed for viability PCR and our current price (ex works) of 80€ for 1 mg (2x 0.5mg) is highly competitive and moreover also includes the non transferable license rights.